Category Regulatory

Exelixis Reports Q3 2024 Financial Results and Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) released its third-quarter financial results for 2024 and highlighted recent progress across key commercial, clinical, and pipeline milestones. Key Developments and Corporate Updates Pipeline and Clinical Trials Cabozantinib Franchise Revenue: The cabozantinib franchise generated $478.1 million…

Read MoreExelixis Reports Q3 2024 Financial Results and Corporate Update

Dr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row

Dr. Reddy’s Laboratories Ltd. has been recognized as one of the top employers in the 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine, marking the company’s third consecutive year on the prestigious list. In the 2022 survey,…

Read MoreDr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row

Maze Therapeutics Announces Positive Phase 1 Data for MZE829 in Treating APOL1 Kidney Disease

Maze Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging human genetics to create innovative small molecule precision medicines for common diseases, has announced promising results from the Phase 1 clinical trial of its drug candidate MZE829 in healthy volunteers. MZE829…

Read MoreMaze Therapeutics Announces Positive Phase 1 Data for MZE829 in Treating APOL1 Kidney Disease

Evecxia Therapeutics Successfully Completes Pre-IND Meeting with FDA on EVX-101 Development for Depression

Evecxia Therapeutics has announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Psychiatry, Office of Neuroscience, Center for Drug Evaluation and Research. This meeting is pivotal for the…

Read MoreEvecxia Therapeutics Successfully Completes Pre-IND Meeting with FDA on EVX-101 Development for Depression

FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy in Patients with Grade 2 IDH-Mutant Glioma

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals,…

Read MoreFDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy in Patients with Grade 2 IDH-Mutant Glioma

FDA Grants Priority Review for Gepotidacin to Treat Uncomplicated UTIs in Women and Adolescents

GSK’s Gepotidacin Accepted for FDA Priority Review to Treat Uncomplicated UTIs GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gepotidacin, a first-in-class oral antibiotic with a…

Read MoreFDA Grants Priority Review for Gepotidacin to Treat Uncomplicated UTIs in Women and Adolescents

FDA Clears SPECTRALIS Flex Module, Enhancing Advanced Ophthalmic Imaging for Underserved Patients

Heidelberg Engineering, a leading provider of ophthalmic imaging and healthcare data solutions, has announced that the FDA has granted clearance for its SPECTRALIS® Flex Module. This advanced, multimodal imaging platform is specifically designed to perform diagnostic imaging of the posterior…

Read MoreFDA Clears SPECTRALIS Flex Module, Enhancing Advanced Ophthalmic Imaging for Underserved Patients